Flecainide and elevated liver enzymes in α1-antitrypsin deficiency

deficiency David J.A. Jenkins, MD, PhD, FRCP, Michael Freeman, MD, FRCPC, Iqwal Mangat, MD, FRCPC, Koruba Srichaikul, MD, MSc, Viranda H. Jayalath, MSc, Dorothea Faulkner, RD, PhD, John L. Sievenpiper, MD, PhD, FRCPC, Cyril W.C. Kendall, PhD, Alexander Romaschin, PhD, Young-In Kim, MD, FRCPC, Paul Dorian, MD, FRCPC, FHRS From the Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, and Clinical Nutrition and Risk Factor Modification Center, St Michael's Hospital, Toronto, Ontario, Canada, Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, Division of Endocrinology and Metabolism, St Michael's Hospital, Toronto, Ontario, Canada, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, Division of Cardiology, Department of Cardiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, Department of Clinical Chemistry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada, Division of Gastroenterology, Department of Medicine, University of Toronto and St Michael's Hospital, Toronto, Canada, Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St Michael’s Hospital, Toronto, Ontario, Canada, and Department of Family and Community Medicine, St Michael's Hospital and Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.